Q3 saw financial improvements for the company, with revenue and adjusted EBITDA beating expectations at $2,786 million and $604 million, respectively. This led to adjusted earnings per share of $1.63. The company raised its full-year guidance for revenue, adjusted EBITDA, and adjusted diluted EPS. The Technology & Analytics Solutions segment saw revenue growth of 10.2%, while R&D Solutions revenue grew 2.6% excluding pass-throughs. Contract Sales & Medical Solutions revenue declined by 13.9%. The R&D Solutions backlog increased by 18.5% to $21.7 billion. The company's outlook for 2021 is positive, with expected revenue growth of 10.1% to 12.8%, adjusted EBITDA growth of 16.1% to 19.3%, and adjusted earnings per share growth of 21.4% to 26.2%. This growth is attributed to expectations of improved business conditions, the recovery of the majority of the business to normalcy, and a continuation of tailwinds from COVID-related work. Due to strong cash flow and liquidity, the company has lifted the suspension of its share repurchase program.